• FirefoxUpgrade to the new Firefox »
  •  Dow Down0.05% Nasdaq Up0.10%

    TrovaGene, Inc. (TROV)

    -NasdaqCM
    5.92 Down 0.03(0.54%) 2:48PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    TrovaGene, Inc.
    11055 Flintkote Avenue
    Suite B
    San Diego, CA 92121
    United States - Map
    Phone: 858-952-7570
    Website: http://www.trovagene.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:25

    Business Summary 

    Trovagene, Inc. develops its proprietary technology for the detection and monitoring of circulating tumor DNA in both urine and blood. Its technology detects and quantitates oncogene mutations in cancer patients for improved disease management. The company’s Precision Cancer Monitoring platform is designed to provide clinical information, such as response to treatment and resistance to therapy from a simple urine or blood sample. Its technology for the detection and monitoring of cell-free DNA in urine could be applied in various disease settings, such as infectious disease, transplantation monitoring, and prenatal genetic diagnostics. Trovagene, Inc. has a clinical collaboration with Genomac Research Institute to demonstrate clinical utility in lung and colorectal cancer treatment monitoring. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on TrovaGene, Inc.

    Key Executives 
     PayExercised
    Dr. Antonius P. Schuh Ph.D., 51
    Chief Exec. Officer and Director
    533.00K0.00
    Mr. Stephen L. Zaniboni MBA, CPA, 57
    Chief Financial Officer and Principal Accounting Officer
    333.00K0.00
    Dr. Mark Erlander Ph.D.,
    Chief Scientific Officer
    269.00K0.00
    Dr. Gary S. Jacob Ph.D., 68
    Sec., Independent Director, Member of Audit Committee and Member of Compensation Committee
    45.00K0.00
    Mr. B. Keith Mccormick MBA,
    VP of Sales & Marketing
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders